1 – 10 of 75
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
Bååth, Maria LU ; Jönsson, Jenny-Maria LU ; Westbom Fremer, Sofia LU
; Martin de la Fuente, Laura
LU
; Tran, Lena
LU
; Malander, Susanne
LU
; Kannisto, Päivi
LU
; Måsbäck, Anna
LU
; Honeth, Gabriella
LU
and Hedenfalk, Ingrid
LU
(2021)
In Genes
12(5).
Mark
-
Homologous recombination repair mechanisms in serous endometrial cancer
Jönsson, Jenny Maria LU ; Bååth, Maria LU ; Björnheden, Ida ; Sahin, Irem Durmaz LU ; Måsbäck, Anna LU and Hedenfalk, Ingrid LU
(2021)
In Cancers
13(2).
Mark
- Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
-
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
Kaminska, Kamila LU ; Akrap, Nina LU ; Staaf, Johan LU
; Alves, Carla L
; Ehinger, Anna
LU
; Ebbesson, Anna
LU
; Hedenfalk, Ingrid
LU
; Beumers, Lukas
LU
; Veerla, Srinivas
LU
and Harbst, Katja
LU
, et al.
(2021)
In Breast cancer research : BCR
23(1).
p.26-26
Mark
-
Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression
Stenström, Jenny ; Hedenfalk, Ingrid LU
and Hagerling, Catharina
LU
(2021)
In Breast Cancer Research
23(1).
Mark
-
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
Haugen, Mads H. ; Lingjærde, Ole Christian ; Hedenfalk, Ingrid LU
; Garred, Øystein
; Borgen, Elin
; Loman, Niklas
LU
; Hatschek, Thomas
; Børresen-Dale, Anne Lise
; Naume, Bjørn
and Mills, Gordon B.
, et al.
(2021)
In JCO Precision Oncology
5.
p.286-306
Mark
- 2020
-
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Martin de la Fuente, Laura LU ; Westbom-Fremer, Sofia LU
; Arildsen, Nicolai Skovbjerg
LU
; Hartman, Linda
LU
; Malander, Susanne
LU
; Kannisto, Päivi
LU
; Måsbäck, Anna
LU
and Hedenfalk, Ingrid
LU
(2020)
In Virchows Archiv : an international journal of pathology
477(1).
p.83-91
Mark
-
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
Bååth, Maria LU ; Westbom-Fremer, Sofia LU
; Martin de la Fuente, Laura
LU
; Ebbesson, Anna
LU
; Davis, Juliette
; Malander, Susanne
LU
; Måsbäck, Anna
LU
; Kannisto, Päivi
LU
and Hedenfalk, Ingrid
LU
(2020)
In Molecular and Cellular Oncology
7(6).
Mark
-
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
Corvigno, Sara ; Mezheyeuski, Artur ; De La Fuente, Laura Martin LU ; Westbom-Fremer, Sofia LU
; Carlson, Joseph W.
; Fernebro, Josefin
LU
; Åvall-Lundqvist, Elisabeth
; Kannisto, Paivi
LU
; Hedenfalk, Ingrid
LU
and Malander, Susanne
LU
, et al.
(2020)
In Gynecologic Oncology
159(3).
p.860-868
Mark
-
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
Arildsen, Nicolai Skovbjerg LU and Hedenfalk, Ingrid LU
(2020)
In Oncotarget
11(40).
p.3660-3674
Mark